$85M LA Biomanufacturing Site Takes Shape In Tarzana

Instal Bio tarzana facility rendering
Courtesy of CBRE
A Rendering Of A Planned Instil Bio Facility In Tarzana, California.

An $85M construction loan will bolster biomanufacturing and biotech in the growing Los Angeles life sciences market.

Instil Bio, a clinical-stage biopharma firm developing cell therapies to fight cancer, secured the funding to build a 102K SF lab, office and commercial manufacturing project in Tarzana, California. The site will be used for research and cell therapy.

CBRE arranged the five-year, floating rate, interest only, nonrecourse loan for the property, which Instil purchased in the fall of 2020.

The development underscores the significant national need for biomanufacturing facilities, especially in demand due to the growth of cell and gene therapy, and the emergence of Los Angeles as a biotech market.

The LA region received $1.9B in National Institutes of Health funding, and according to a recently released CBRE report exploring biotech talent across the country, Los Angeles was ranked seventh nationwide. The region produces the second-most graduates in biological and biomedical sciences.

Continue reading this story with a free account

Log in or register
Related Topics: Life Sciences Lab Space
Sign up for more articles like this
Subscribe to Bisnow's National Newsletters
Related Stories

Fed Raises Benchmark Rate, Intensifying Borrowing Cost Blues

Inside The Nationwide Jockeying For Opportunity Zones 2.0

GTIS Partners Rebrands As Brightshore Capital, Launches $250M Debt Platform

Data Center Spills 5,000 Gallons Of Fuel Into New Jersey River

Hines And Rialto Close Office Credit Fund At $1.1B

Chipotle Adding Hundreds Of New Locations Worldwide

'Beyond A Routine Wobble': 10-Year Treasury Clears 5% Ahead Of Key Fed Meeting

Trump's DEI Crackdown Is Creating New Risks For Landlords That Lease To The Government

Taconic Partners Sheds Another NYC Life Sciences Property

Airbnb Launches $250M Fund To Invest In Affordable Housing

Brookfield Buys Minority Stake In Hyperscale Data Center Developer AREP

Judge Dismisses Suit Alleging Alexandria Misled Investors Over Portfolio Strength